TITLE:
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

CONDITION:
Diabetic Nephropathy

INTERVENTION:
LY333531

SUMMARY:

      The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary
      albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2)
      Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that
      may be associated with it.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 30 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Greater than or equal to 30 years of age

          -  Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without
             language barrier.

        Exclusion Criteria:

          -  Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females

          -  B/P greater than 150 systolic and greater than 90 diastolic

          -  Hemoglobin Alc greater than 11%

          -  Liver Function Tests 2 times upper limit of normal

          -  Poor medical or psychiatric risk.
      
